GLP-1 Drugs Show Promise in Cancer and Cognitive Health

Recent studies have indicated that GLP-1 drugs, such as Ozempic, may have potential benefits in cancer prevention, although results vary significantly across different research. A meta-analysis of 26 randomized trials involving over 160,000 patients showed a statistically significant reduction in dementia risk and cognitive impairment associated with GLP-1 therapies, highlighting their emerging role in neurological conditions. However, the findings also underscore the need for more well-designed, long-term trials to clarify these effects.
